CONCORD BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,486 INR | +5.17% |
|
+6.47% | +0.97% |
Valuation
| Fiscal Period: March | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 155,465 | - | - |
| Enterprise Value (EV) 1 | 159,100 | 154,922 | 154,820 |
| P/E ratio | 51.6 x | 39.8 x | 31.1 x |
| Yield | 0.42% | 0.67% | 0.84% |
| Capitalization / Revenue | 15.6 x | 12.5 x | 10.2 x |
| EV / Revenue | 15.6 x | 12.4 x | 10.2 x |
| EV / EBITDA | 36.9 x | 29 x | 23 x |
| EV / FCF | 170 x | 58.4 x | 48 x |
| FCF Yield | 0.59% | 1.71% | 2.08% |
| Price to Book | 10.2 x | 8.53 x | 7.05 x |
| Nbr of stocks (in thousands) | 104,616 | - | - |
| Reference price 2 | 1,486 | 1,486 | 1,486 |
| Announcement Date | 5/24/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 10,169 | 12,453 | 15,192 |
| EBITDA 1 | - | 4,316 | 5,344 | 6,728 |
| EBIT 1 | - | 3,780 | 4,814 | 6,159 |
| Operating Margin | - | 37.17% | 38.65% | 40.54% |
| Earnings before Tax (EBT) 1 | - | 4,126 | 5,137 | 6,580 |
| Net income 1 | 2,401 | 3,081 | 3,902 | 4,984 |
| Net margin | - | 30.3% | 31.33% | 32.8% |
| EPS 2 | 22.95 | 29.45 | 37.38 | 47.72 |
| Free Cash Flow 1 | - | 911.5 | 2,655 | 3,223 |
| FCF margin | - | 9.19% | 21.32% | 21.22% |
| FCF Conversion (EBITDA) | - | 21.56% | 49.68% | 47.91% |
| FCF Conversion (Net income) | - | 30.29% | 68.04% | 64.68% |
| Dividend per Share 2 | - | 6.280 | 9.900 | 12.53 |
| Announcement Date | 7/1/23 | 5/24/24 | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 630 | 2,685 | 3,965 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | 912 | 2,655 | 3,223 |
| ROE (net income / shareholders' equity) | - | 21.4% | 22.9% | 24.4% |
| ROA (Net income/ Total Assets) | - | 19% | 20% | 22% |
| Assets 1 | - | 15,837 | 19,509 | 22,652 |
| Book Value Per Share 2 | - | 146.0 | 174.0 | 211.0 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 1,433 | 550 | 600 |
| Capex / Sales | - | 14.45% | 4.42% | 3.95% |
| Announcement Date | 7/1/23 | 5/24/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1,486
INR
Average target price
1,592
INR
Spread / Average Target
+7.13%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.97% | 1.77B | |
| -0.28% | 90.59B | |
| 0.00% | 38.99B | |
| -8.62% | 34.09B | |
| +64.13% | 26.38B | |
| -17.56% | 15.02B | |
| -5.92% | 13.17B | |
| -10.69% | 11.88B | |
| -47.78% | 10.65B | |
| +8.09% | 9.25B |
- Stock Market
- Equities
- CONCORDBIO Stock
- Financials Concord Biotech Limited
